Evgen Pharma PLC (AIM: EVG), renowned for its advancements in sulforaphane-based medicine, recently revamped its board structure.
Evgen Pharma PLC (AIM: EVG), renowned for its advancements in sulforaphane-based medicine, recently revamped its board structure.
Evgen Pharma PLC (AIM: EVG) has revealed the conclusive data from its Phase 1b study, which evaluated the new enteric-coated tablet formulation of its primary drug, SFX-01.
Evgen Pharma PLC (AIM: EVG), a clinical-stage pharmaceutical development firm, has disclosed the termination of its patent and knowledge licence agreement with JuvLife Ltd, a subsidiary of Juvenescence Ltd.
First healthy volunteers dosed on schedule
SFX-01 licensing deal for up to $160.5m in milestone payments expands lead asset into neurodevelopmental disorders
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of cancers and inflammation, announces that it has progressed discussions with the
Publication shows effectiveness of SFX-01 in patient derived glioblastoma cells University of Auckland data
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces preclinical data demonstrating that SFX-01 was effective in
AN Army officer is tackling a week of 24-hour endurance events with no rest to raise funds and awareness for a veterans’ mental health charity.
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces further progress and an update on clinical trial plans for SFX-01 in glioblastoma (“GBM”).
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company, is delighted to announce participation in the recently notified funding initiative for COVID-19 clinical trials by the medical research